IL241178B - History of phenylacetic acid and 3-phenylacetic acid for the treatment of leprosy - Google Patents

History of phenylacetic acid and 3-phenylacetic acid for the treatment of leprosy

Info

Publication number
IL241178B
IL241178B IL241178A IL24117815A IL241178B IL 241178 B IL241178 B IL 241178B IL 241178 A IL241178 A IL 241178A IL 24117815 A IL24117815 A IL 24117815A IL 241178 B IL241178 B IL 241178B
Authority
IL
Israel
Prior art keywords
phenylacetic acid
derivatives
treating fibrosis
fibrosis diseases
diseases
Prior art date
Application number
IL241178A
Other languages
English (en)
Hebrew (he)
Other versions
IL241178A0 (en
Original Assignee
Prometic Pharma Smt Ltd
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd, Prometic Biosciences Inc filed Critical Prometic Pharma Smt Ltd
Publication of IL241178A0 publication Critical patent/IL241178A0/en
Publication of IL241178B publication Critical patent/IL241178B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
IL241178A 2013-03-15 2015-09-03 History of phenylacetic acid and 3-phenylacetic acid for the treatment of leprosy IL241178B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798269P 2013-03-15 2013-03-15
PCT/CA2014/000236 WO2014138906A1 (en) 2013-03-15 2014-03-14 Substituted aromatic compounds and related method for the treatment of fibrosis

Publications (2)

Publication Number Publication Date
IL241178A0 IL241178A0 (en) 2015-11-30
IL241178B true IL241178B (en) 2020-09-30

Family

ID=51535669

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241178A IL241178B (en) 2013-03-15 2015-09-03 History of phenylacetic acid and 3-phenylacetic acid for the treatment of leprosy

Country Status (25)

Country Link
US (3) US10023518B2 (OSRAM)
EP (1) EP2970089B1 (OSRAM)
JP (1) JP6448562B2 (OSRAM)
KR (1) KR102196721B1 (OSRAM)
CN (2) CN105189438A (OSRAM)
AR (1) AR095429A1 (OSRAM)
AU (1) AU2014231648B2 (OSRAM)
BR (1) BR112015022008A2 (OSRAM)
CA (1) CA2905621C (OSRAM)
CL (1) CL2015002535A1 (OSRAM)
DK (1) DK2970089T3 (OSRAM)
EA (1) EA030651B1 (OSRAM)
ES (1) ES2741439T3 (OSRAM)
IL (1) IL241178B (OSRAM)
MX (1) MX379424B (OSRAM)
MY (1) MY180305A (OSRAM)
NZ (1) NZ712797A (OSRAM)
PH (1) PH12015502011B1 (OSRAM)
PL (1) PL2970089T3 (OSRAM)
PT (1) PT2970089T (OSRAM)
SG (1) SG11201507408XA (OSRAM)
TW (1) TWI689490B (OSRAM)
UY (1) UY35402A (OSRAM)
WO (1) WO2014138906A1 (OSRAM)
ZA (1) ZA201507061B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
PL3203999T3 (pl) * 2014-10-10 2020-07-27 Liminal Biosciences Limited Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy
CA2963276A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
KR20170072352A (ko) * 2014-11-12 2017-06-26 프로메틱 파마 에스엠티 리미티드 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물
DK3271326T3 (da) * 2015-03-18 2021-01-25 Vectus Biosystems Ltd Sammensætninger til behandling af nyre- og/eller leversygdom
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US20190144547A1 (en) * 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
JP6718522B2 (ja) * 2016-05-19 2020-07-08 長弘生物科技股▲ふん▼有限公司 肺線維症の発症および/または治療の遅延のための医薬製剤
CN110366425A (zh) 2016-12-15 2019-10-22 泰伦基国际有限公司 一种预防动脉粥样硬化及其并发症的方法
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
KR102126389B1 (ko) * 2018-09-14 2020-06-25 셀라이온바이오메드 주식회사 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물
CA3112073A1 (en) 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof
CA3195137A1 (en) * 2020-10-06 2022-04-14 Lyne Gagnon Substituted aromatic compounds and pharmaceutical compositions thereof
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
WO2007140189A2 (en) * 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
ES2657484T3 (es) * 2007-02-08 2018-03-05 Emisphere Technologies, Inc. Agentes de administración de ácido fenilalquilcarboxílico
WO2010127440A1 (en) * 2009-05-04 2010-11-11 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical uses thereof
KR20120090011A (ko) * 2009-05-04 2012-08-16 프로메틱 바이오사이언시즈 인코포레이티드 3-펜틸페닐아세트산의 염 및 이의 약학적 용도
AT509045B1 (de) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale

Also Published As

Publication number Publication date
PL2970089T3 (pl) 2020-01-31
CN105189438A (zh) 2015-12-23
PT2970089T (pt) 2019-09-04
PH12015502011B1 (en) 2020-12-04
EA201591775A1 (ru) 2016-05-31
ZA201507061B (en) 2017-03-26
MY180305A (en) 2020-11-27
AU2014231648B2 (en) 2018-02-08
NZ712797A (en) 2020-08-28
US20180237374A1 (en) 2018-08-23
AR095429A1 (es) 2015-10-14
SG11201507408XA (en) 2015-10-29
MX379424B (es) 2025-03-11
US10550066B2 (en) 2020-02-04
EP2970089A4 (en) 2016-10-12
IL241178A0 (en) 2015-11-30
CN110105200B (zh) 2022-04-12
EA030651B1 (ru) 2018-09-28
EP2970089A1 (en) 2016-01-20
CN110105200A (zh) 2019-08-09
WO2014138906A1 (en) 2014-09-18
US10023518B2 (en) 2018-07-17
JP6448562B2 (ja) 2019-01-09
KR20160051676A (ko) 2016-05-11
US20200172462A1 (en) 2020-06-04
US20160039736A1 (en) 2016-02-11
CL2015002535A1 (es) 2016-03-28
ES2741439T3 (es) 2020-02-11
AU2014231648A1 (en) 2015-10-22
KR102196721B1 (ko) 2020-12-30
UY35402A (es) 2014-10-31
US11524930B2 (en) 2022-12-13
PH12015502011A1 (en) 2016-01-11
BR112015022008A2 (pt) 2021-05-25
DK2970089T3 (da) 2019-08-05
CA2905621C (en) 2021-06-29
EP2970089B1 (en) 2019-05-08
JP2016512202A (ja) 2016-04-25
MX2015011878A (es) 2016-06-07
TW201441186A (zh) 2014-11-01
HK1220440A1 (en) 2017-05-05
TWI689490B (zh) 2020-04-01
CA2905621A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IL241178B (en) History of phenylacetic acid and 3-phenylacetic acid for the treatment of leprosy
IL270347B (en) Therapeutically active compounds and methods of use
IL237638B (en) Heteroaryl c17 derivatives of olanolic acid and methods of using them
ZA201600667B (en) Therapeutically active compounds and their methods of use
IL237070A0 (en) Treatment of vaccine-related diseases and inflammatory diseases
PL2882779T3 (pl) Pochodna kwasu hialuronowego, sposób jej wytwarzania, sposób jej modyfikacji i jej zastosowanie
EP3060217A4 (en) Treatment of polycystic diseases with an hdac6 inhibitor
IL239851A0 (en) Methods and compositions for treating diseases that act to remove myelin
PT3021839T (pt) Composições para o tratamento da fibrose
EP2941252A4 (en) USE OF FATTY ACID NIACIN CONJUGATES FOR THE TREATMENT OF DISEASES
IL234726A0 (en) Catheter and its manufacturing method
IL234606B (en) Novel methods and composition for treatment of disease
IL239273A0 (en) A method of treating diseases
IL241096A0 (en) Treatment methods
EP2986112A4 (en) PREPARATION AND USE OF FULVINIC ACID DERIVATIVES
EP3004069A4 (en) HUMINIC ACID DERIVATIVES AND METHOD FOR THE PREPARATION AND USE
TWI559918B (en) Use of gallic acid and its pharmaceutically acceptable salt
ZA201602304B (en) Modified anti-inflammatory proteins and method of use
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
AU2013904712A0 (en) Method of Treatment
AU2013904170A0 (en) Method of treatment
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed